Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.

MLA

Koutsilieris, Michael, et al. “Combination of Somatostatin Analogues and Dexamethasone (Anti-Survival-Factor Concept) with Luteinizing Hormone-Releasing Hormone in Androgen Ablation-Refractory Prostate Cancer with Bone Metastasis.” BJU International, vol. 100 Suppl 2, July 2007, pp. 60–62. EBSCOhost, https://doi.org/10.1111/j.1464-410X.2007.06958.x.

APA

Koutsilieris, M., Dimopoulos, T., Milathianakis, C., Bogdanos, J., Karamanolakis, D., Pissimissis, N., Halapas, A., Lembessis, P., Papaioannou, A., & Sourla, A. (2007). Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU International, 100 Suppl 2, 60–62. https://doi.org/10.1111/j.1464-410X.2007.06958.x

Chicago

Koutsilieris, Michael, Theodore Dimopoulos, Constantine Milathianakis, John Bogdanos, Dimitrios Karamanolakis, Nicholas Pissimissis, Antonis Halapas, Peter Lembessis, Andreas Papaioannou, and Antigone Sourla. 2007. “Combination of Somatostatin Analogues and Dexamethasone (Anti-Survival-Factor Concept) with Luteinizing Hormone-Releasing Hormone in Androgen Ablation-Refractory Prostate Cancer with Bone Metastasis.” BJU International 100 Suppl 2 (July): 60–62. doi:10.1111/j.1464-410X.2007.06958.x.